Longbio Pharma (Suzhou) Co (HKSE:01779) Research & Development: HK$ Mil (TTM As of Dec. 2025)


HKSE:01779 Longbio Pharma (Suzhou) Co Ltd HKSE:01779
10 GF Score
Price HK$157.20
View Full Analysis

What is Longbio Pharma (Suzhou) Co Research & Development?

Longbio Pharma (Suzhou) Co HKSE:01779 +3.63% 10 Research & Development is HK$ Mil as of Dec. 2025. GuruFocus rates HKSE:01779 with a GF Score™ of 10/100.

Research & Development is the aggregate amount of research and development expenses during the year. Longbio Pharma (Suzhou) Co's Research & Development for the six months ended in Dec. 2025 was HK$139.88 Mil. Longbio Pharma (Suzhou) Co does not have enough years/quarters to calculate the Research & Development for the trailing twelve months (TTM) ended in Dec. 2025.

Longbio Pharma (Suzhou) Co  (HKSE:01779) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Longbio Pharma (Suzhou) Co Research & Development Related Terms

Longbio Pharma (Suzhou) Co Research & Development Historical Data

* Premium members only.

The historical data trend for Longbio Pharma (Suzhou) Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longbio Pharma (Suzhou) Co Research & Development Chart

Longbio Pharma (Suzhou) Co Annual Data
Trend Dec24 Dec25
Research & Development
104.72 139.88

Longbio Pharma (Suzhou) Co Semi-Annual Data
Dec24 Dec25
Research & Development 104.72 139.88
HKSE:01779
10GF Score
Longbio Pharma (Suzhou) Co Ltd HKSE:01779
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longbio Pharma (Suzhou) Co Research & Development Calculation

This is the expense the company spent on research and development.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$ Mil mean?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a Research & Development of HK$ Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Longbio Pharma (Suzhou) Co and its competitors.
Is Longbio Pharma (Suzhou) Co's Research & Development too high?
Longbio Pharma (Suzhou) Co's current Research & Development is HK$ Mil. Overall, Longbio Pharma (Suzhou) Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Longbio Pharma (Suzhou) Co's Research & Development compare to ?
Longbio Pharma (Suzhou) Co's Research & Development of HK$ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Longbio Pharma (Suzhou) Co and its competitors. Longbio Pharma (Suzhou) Co's current Research & Development is HK$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longbio Pharma (Suzhou) Co stock overvalued right now?
Longbio Pharma (Suzhou) Co (HKSE:01779) has a current Research & Development of HK$ Mil. The current Research & Development is HK$ Mil. Longbio Pharma (Suzhou) Co's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Longbio Pharma (Suzhou) Co (HKSE:01779), the current Research & Development is HK$ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longbio Pharma (Suzhou) Co Business Description

Comparable Companies
Address No. 128 Yinhe Road, Dongnan Subdistrict, 5th Floor, Building F, Area A, Changshu City, Jiangsu Province, Suzhou, CHN
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
10GF Score

Get the complete analysis for HKSE:01779

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$157.20
Price